Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Momenta, Sandoz develop and market complex drugs; expanded in separate deal

Executive Summary

Momenta (sugar sequencing and engineering) will combine its complex sugars technologies with the expertise of Novartis' generic unit Sandoz to jointly develop and market a generic equivalent of injectable enoxaparin--generic of Lovenox-- and potential improved forms of it. The drug is a low-molecular weight heparin for preventing and treating deep vein thrombosis and for treating acute coronary syndromes.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies